A groundbreaking Alzheimer’s drug called donanemab has been denied widespread use in the NHS in England. The UK’s medicines regulator approved the drug, but the National Institute of Health and Care Excellence (NICE) stated that it does not show enough value for the NHS. This rejection marks the second time an innovative Alzheimer’s treatment has been turned down by NICE.
Donanemab, also known as Kisunla, is developed by Eli Lilly and is a targeted antibody drug that slows down the early stages of Alzheimer’s. Along with another drug called lecanemab, these treatments focus on addressing the root cause of the disease, unlike traditional methods that only manage symptoms.
NICE’s decision was based on the cost-effectiveness of donanemab. While the drug has shown potential in slowing cognitive decline by four to seven months, the additional cost to the NHS was deemed too high. Despite the disappointment, there are ongoing developments in Alzheimer’s research, and new treatments are in the pipeline.
Both donanemab and lecanemab target a protein called amyloid, which accumulates in the brains of Alzheimer’s patients. By binding to this protein, the drugs aim to clear the build-up and slow cognitive decline, especially if administered in the early stages of the disease. Clinical trials have shown promising results, indicating a significant reduction in memory loss and improvements in daily activities.
Although the drugs have been approved for use in the US, European regulators have been more cautious. The cost of donanemab could range from £500m to £1bn per year for NHS England, leading to concerns about creating a two-tier system for Alzheimer’s patients. Those who can afford the treatment privately may have access, while NHS-dependent individuals might be left without.
Alzheimer’s Research UK expressed disappointment over the decision, highlighting the frustration faced by those affected by the disease. While donanemab is considered the most effective treatment to date, its high cost has limited its accessibility in the UK. Patients may need to explore private options, which can be financially burdensome.
The rejection of donanemab reflects the challenges in balancing effectiveness, cost, and accessibility in healthcare. Despite setbacks, researchers continue to explore new avenues for Alzheimer’s treatment, offering hope for future breakthroughs that may address these concerns. The focus remains on finding safe, effective, and affordable solutions to combat Alzheimer’s disease.